Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IRON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIRONDisc Medicine$52.71+3.6%$45.20$30.82▼$68.73$1.83B0.73349,922 shs396,507 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIRONDisc Medicine-4.16%+7.48%+9.12%-2.96%+29.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIRONDisc Medicine2.1911 of 5 stars3.52.00.00.02.32.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIRONDisc Medicine 3.09Buy$96.7083.46% UpsideCurrent Analyst Ratings BreakdownLatest JAY, IRON, VAST, and SML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025IRONDisc MedicineRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageStrong-Buy$89.005/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%8/6/2025 (Estimated)Latest JAY, IRON, VAST, and SML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIRONDisc MedicineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIRONDisc MedicineN/A19.3619.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIRONDisc Medicine83.70%Insider OwnershipCompanyInsider OwnershipIRONDisc Medicine4.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIRONDisc Medicine3034.63 million28.50 millionNot OptionableCRTM, IRON, ARK, and ALBA HeadlinesRecent News About These CompaniesDisc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual CongressJune 12 at 7:30 AM | globenewswire.comCantor Fitzgerald Comments on Disc Medicine FY2026 EarningsJune 12 at 2:49 AM | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Coverage Initiated by Analysts at Raymond JamesJune 11 at 10:18 AM | marketbeat.comCantor Fitzgerald Forecasts Disc Medicine FY2026 EarningsJune 10 at 8:57 AM | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 2,996 Shares of StockJune 10 at 5:20 AM | insidertrades.comWilliam Jacob Savage Sells 2,996 Shares of Disc Medicine, Inc. (NASDAQ:IRON) StockJune 9 at 11:26 PM | marketbeat.comMillennium Management LLC Buys Shares of 7,879 Disc Medicine, Inc. (NASDAQ:IRON)June 9 at 3:22 AM | marketbeat.comAmeriprise Financial Inc. Invests $335,000 in Disc Medicine, Inc. (NASDAQ:IRON)June 6, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Receives $98.80 Average Price Target from BrokeragesJune 6, 2025 | americanbankingnews.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 74,454 Shares of Disc Medicine, Inc. (NASDAQ:IRON)June 3, 2025 | marketbeat.comBank of America Corp DE Reduces Position in Disc Medicine, Inc. (NASDAQ:IRON)June 3, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Receives Average Rating of "Buy" from AnalystsJune 3, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Nuveen Asset Management LLCJune 2, 2025 | marketbeat.comWellington Management Group LLP Sells 444,821 Shares of Disc Medicine, Inc. (NASDAQ:IRON)May 30, 2025 | marketbeat.comDisc Medicine to Participate in Upcoming Investor ConferencesMay 28, 2025 | globenewswire.comDisc Medicine, Inc. (NASDAQ:IRON) Stock Position Raised by Deutsche Bank AGMay 28, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 742,423 Shares of Disc Medicine, Inc. (NASDAQ:IRON)May 25, 2025 | marketbeat.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Insider Sells 6,677 Shares of StockMay 23, 2025 | insidertrades.comWoodline Partners LP Boosts Stake in Disc Medicine, Inc. (NASDAQ:IRON)May 23, 2025 | marketbeat.comDisc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Rafferty Asset Management LLCMay 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Acquires Shares of 81,190 Disc Medicine, Inc. (NASDAQ:IRON)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAmong the Market’s Most Shorted: 2 Firms With +40% Short InterestBy Leo Miller | June 3, 2025View Among the Market’s Most Shorted: 2 Firms With +40% Short InterestUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?AXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionBy Leo Miller | May 31, 2025View AXON: Competition Intensifies as Motorola Makes $4.4B AcquisitionD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsCRTM, IRON, ARK, and ALBA Company DescriptionsDisc Medicine NASDAQ:IRON$52.71 +1.85 (+3.64%) As of 04:00 PM EasternDisc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
